

The cyclophilin A binding loop of capsid regulates the human TRIM5α sensitivity of non-pandemic HIV-1

Augustin P. Twizerimana¹, Daniel Becker², Shenglin Zhu¹, Tom Luedde¹, Holger Gohlke^{2,3}, Carsten Münk^{1,#}

¹Clinic of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

²Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

³Forschungszentrum Jülich GmbH, Institute of Bio- and Geosciences (IBG-4: Bioinformatics), Jülich, Germany

Classification: BIOLOGICAL SCIENCES, Microbiology

Keywords: HIV-1, TRIM5, restriction factor, cyclophilin, capsid

[#]Corresponding author: Carsten Münk, Clinic for Gastroenterology, Hepatology, and Infectiology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany. Germany, Tel: +49 (0) 211-81-08720, carsten.muenk@med.uni-duesseldorf.de.

Abstract

The rather few cases of humans infected by HIV-1 N, O, or P raise the question of their incomplete adaptation to humans. We hypothesized that early post-entry restrictions may be relevant for the impaired spread of these HIVs. One of the best-characterized species-specific restriction factors is TRIM5 α . HIV-1 M can escape human TRIM5 α restriction by binding cyclophilin A (CYPA, also known as PPIA, peptidylprolyl isomerase A) to the so-called CYPA binding loop of its capsid protein. How non-M HIV-1s interact with huTRIM5 α is ill-defined. By testing novel full-length reporter viruses (Δenv) of HIV-1 N, O, P, and SIVgor, we found that, in contrast to HIV-1 M, the non-pandemic HIVs and SIVgor showed restriction by human TRIM5 α . Work to identify capsid residues that mediate susceptibility to huTRIM5 α revealed that capsid residue 88 in the capsid CYPA binding loop was important for such differences. There, HIV-1 M uses alanine to resist, while non-M HIV-1s have either valine or methionine, which avail them for huTRIM5 α . Capsid residue 88 determines the sensitivity to TRIM5 α in a so far unknown way. Molecular simulations indicated that capsid residue 88 can affect *trans*-to-*cis* isomerization patterns on the capsids of the viruses we tested. These differential CYPA usages by pandemic and non-pandemic HIV-1 suggest that the enzymatic activity of CYPA on the viral core might be important for its protective function against human TRIM5 α .

Significance statement

Almost all cases of HIV-1 infections are caused by the pandemic HIV-1 M. The non-pandemic HIV-1s N, O, and P do not spread much in humans for unknown reasons. Human cells express TRIM5 α that restricts HIV-1. HIV-1 M evolved to escape this restriction by binding cyclophilin A to the viral core. Our data indicate that non-pandemic HIV-1s are sensitive to human TRIM5 α . In these viruses, cyclophilin A binding cannot protect against TRIM5 α , because its *trans/cis* isomerase enzymatic activity is reduced. Our data suggest that subtle changes induced by cyclophilin A in the capsid have a severe impact on viral infection.

Introduction

Human immunodeficiency virus 1 (HIV-1) is subdivided into four groups, the pandemic group M, and the non-pandemic groups N, O, and P (1). HIV-1 N was identified in 20 patients and HIV-1 P in two patients, circulating mostly in Cameroon (<https://www.hiv.lanl.gov/>). About 100.000 people have been infected with HIV-1 group O found in West and Central Africa with the highest prevalence in Cameroon, Gabun and Equatorial Guinea (2). HIV-1s are the evolutionary results of rare successful transmission events of simian immunodeficiency viruses (SIV) to humans. Group M and group N HIV-1s are derived from SIV of chimpanzees (SIVcpz), while group O and group P are the results of spillover of SIV of gorillas (SIVgor) (1, 3, 4). To halt retroviral replication, vertebrates use several cellular restriction factors (5–9). It is ill-defined whether the low prevalence of non-M HIVs is associated with the activity of antiviral factors such as the capsid-binding TRIM5 α , which may limit their spread among humans.

TRIM proteins have a RING domain, a coiled-coil domain, and one to two B box domains (10). In addition, some TRIM proteins have a C-terminal PRYSPRY (B30.2) domain such as

in the alpha isoform of TRIM5, the TRIM5 α , and TRIM25, or a cyclophilin A (CYPA) domain such as in the TRIM-Cyclophilin A (TRIMCyp) fusion proteins (11). The PRYSPRY or CYPA domains of TRIM5 proteins can bind retroviral cores. This binding initiates TRIM5 oligomerization to form higher-order oligomers around the conical core to affect the core integrity, and, thereby, impairs nuclear import and integration of the reverse-transcribed viral genome (11–13). The TRIM5 α binding to capsid can also result in intracellular signaling events for an extended viral restriction (11, 14). The anti-retroviral activity of TRIM5 proteins has been shown to mainly be PRYSPRY or CYPA domain-dependent (11). CYPA presence at the C-terminus of TRIM5 proteins is a result of the evolutionary retrotransposition of *CYPA* in some primates, like the Old World rhesus monkeys (*Macaca mulatta*) or the New World *Aotus* night/owl monkeys (15, 16). The antiretroviral activity of TRIM5 α is thought to have formed a selective protective shield against the retroviral spread in vertebrate hosts (17, 18). As an example, human (hu) TRIM5 α restricts infections by the horse lentivirus equine infectious anemia virus (EIAV) (19); in contrast, the pandemic HIV-1 M escapes the antiviral activity of huTRIM5 α by displaying binding sites in the viral core for CYPA (20, 21). The viral core is composed of about 1200 – 1500 capsid proteins in mostly hexameric organizations (22). Cellular CYPA and TRIMCyp bind the so-called CYPA binding loop of capsid formed by residues 85 to 93 (23–26). The CYPA - core interaction during the early phase of infection in the viral target cell is essential for its protective function against huTRIM5 α (20). CYPA is also packaged by HIV virions, with less defined roles (27, 28). In virions, a CYPA-capsid stoichiometry of 0.1 and in *in vitro* assembled capsid tubes, a stoichiometry of ~ 0.3–0.4 was described (29–31). CYPA can influence many early steps of HIV infection (32–34) but the molecular mechanisms are not fully understood and may involve a trans/*cis* isomerization activity of CYPA and altered dynamics of the core (35, 36). Here we tested the antiviral property of human TRIM5 α against non-M group HIVs but also SIVgor, identified viral determinants of sensitivity, and assessed the role of CYPA in the mechanism of TRIM5 α to restrict HIVs.

Materials and methods.

Cells. CrFK and HEK293T cells were maintained in Dulbecco's high-glucose modified Eagle's medium (PAN Biotech, Aidenbach, Germany) with addition of 10% fetal bovine serum (FBS, PAN Biotech), 2 mM L-glutamine (PAN Biotech), 100 U/ml penicillin, and 100 μ g/ml streptomycin (PAN Biotech). TRIM5 α knockout U87-MG and control cells were kindly donated by Michael Malim (37); CYPA knockdown and control U87-MG cells were cultured under 1 μ g puromycin. Human macrophages were isolated from whole blood, obtained from the university hospital of Heinrich Heine University Düsseldorf (ethical approval study number 3180). Macrophages were maintained in RPMI 1640 containing 1,000 U/ml monocyte colony-stimulating factor (M-CSF).

Plasmids. The replication-competent HIV-1 N DJO0131, HIV-1 O RBF206, HIV-1 P RBF168, SIVcpzPtt MB897 clones were kindly provided by Frank Kirchhoff. SIVgorCP2139, and SIVcpzP_{ts} clone TAN1.910 clones were obtained from NIH AIDS repository (38). The murine leukemia virus (MLV) packaging construct pHIT60, which encodes the *gag-pol* of Moloney MLV was provided by Jonathan Stoye (39). Reporter viruses for HIV-1 N, HIV-1 O, HIV-1 P, and SIVgor were constructed as follow: Using fusion PCR, *nanoluciferase* gene was cloned in replacement of *nef* of HIV-1 N, HIV-1 O, HIV-1 P, and SIVgor. Two stop codons were introduced in the envelope genes of these viruses, as VSV-G was to be used for envelope. Capsid mutant reporter viruses of HIV-1 M, HIV-1 N, HIV-1 O and HIV-1 P were generated with fusion PCR using specific primers

including those with desired mutations. HIV-1 M with HIV-1 N or HIV-1 O or HIV-1 P capsid were made by fusion PCR, their inserts were cloned in PmlI-MfeI digested pMDLg/pRRE vector to produce chimeric *gag-pol* of HIV-1 M with CA genes of other viruses: pMDLg/pRRE.HIV-1 N CA, pMDLg/pRRE.HIV-1 O CA, pMDLg/pRRE.HIV-1 P CA. Complete *gag-pol* constructs for HIV-1 N, HIV-1 O, and HIV-1 P were constructed using the HIV-1 M pMDLg/pRRE plasmid and replacing HIV-1 M *gag-pol* by digestion with PmlI and BspEI and insertion of *gag-pols* of interest, produced through a series of overlapping PCR reactions, to make pMDLg/pRRE.HIV-1 N, pMDLg/pRRE.HIV-1 O, pMDLg/pRRE.HIV-1 P and pMDLg/pRRE.SIVgor. CYPA binding loop capsid mutants were made through PCR with primers bearing specific CYPA binding loops sequences and their inserts were respectively cloned in specific vectors to make HIV-1 M.N loop, HIV-1 M.O loop, and HIV-1 N.M loop. HIV-1 vector pSIN.PPT.CMV.Luc.IRES.GFP expresses firefly luciferase and GFP. psPAX2 was obtained from the NIH AIDS Reagent Program (Cat# 11348); pRSV-Rev, pMDLg/pRRE and pMD.G (VSV-G) have been described (40). Using fusion PCR on TRIMCyp in pLNCX2 plasmid (41), fusion PCR was used to introduce the desired mutations in the CYPA domain; N66D, H69R or N66D-H69R rhTRIMCyp-HA mutants were generated.

Transfection and viral particle production. The pMDLg/pRRE based viral particles production was done using: pMDLg/pRRE (800 ng), pSIN.PPT.CMV.Luc.IRES.GFP (800 ng), pRSV-Rev (400 ng), and pMDG.VSV-G (200 ng). For nanoluciferase-based reporter viruses (HIV-1 N, O, P, SIVgor, SIVcpz), 10⁶ HEK293T cells were seeded, the following day, these cells were transfected using 200 ng VSV-G and 2000 ng of viral plasmids using polyjet (Tebubio GmbH, Offenbach, Germany). 48 hrs post-transfection, viral particles were collected. Where needed, the reverse transcriptase (RT) activity of viruses was quantified using the previously described approach (42).

Generation of stable cells expressing TRIM5 proteins. Viral particles produced in HEK293T cells using a pLNCX2.TRIMCyp construct, pHIT60, and pMD.G (VSV-G) were used to transduce CrFK cells for three days, followed by a selection under 400 µg/ml G418 (Biochrom GmbH, Berlin, Germany), for the expression of HA-tagged wild type and mutant rhTRIMCyp proteins. Protein expression was confirmed with immunoblots. Cells expressing empty pLNCX2 vector were used for control.

Single round infection assay. 10 x 10⁴ CrFK cells or 5 x 10³ (U-87 MG) cells were seeded into 96-well plates and infection was performed the following day. For experiments involving cyclosporin A (CsA, Sigma Aldrich, Germany), 1 to 10 µM of CsA or control DMSO were used to treat cells 2 hrs before infection. Cells were then infected with different reporter viral particles and after 48 to 72 hrs, luciferase activity was measured. For infection with nanoluciferase-containing reporter viruses, cells were washed with phosphate-buffered saline (PBS) three times before lysis and luciferase measurement, in addition to medium change 24 hrs following infection, to eliminate the effect of background nanoluciferase. Nanoluciferase activity was measured with Nano-Glo Luciferase system (Promega, Mannheim, Germany) and firefly luciferase activity was measured with the Steady-Glo Luciferase system (Promega) on a MicroLumat Plus luminometer (Berthold Detection Systems, Pforzheim, Germany). Each experiment was performed in triplicates for at least three times.

Pulldown assays and immunoblots. The GST-CYPA based pulldown experiments followed a protocol previously described (43). To confirm the expression of primate TRIM5 proteins, cells were lysed using RIPA lysis buffer (25 mM Tris-HCl [pH 8.0], 137 mM NaCl, 1% NP-

40, 1% glycerol, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2 mM EDTA, and protease inhibitor cocktail set III (Calbiochem, Darmstadt, Germany). The cell lysate was centrifuged at 14,800 rpm for 20 min at 4°C. The protein supernatant was denatured using Roti-load sample buffer (Roth, Karlsruhe, Germany) and was used for SDS PAGE. Mouse primary anti-HA (MMS-101P, Covance, Münster, Germany, 1:7.500 dilution) for HA-tagged proteins, anti-human TRIM5 α (rabbit monoclonal, # 143265; Cell Signaling Technology Europe BV, Frankfurt, Germany), anti-CYPA (mouse monoclonal; Santa Cruz Biotechnology) (1:500 dilution), CYPA.GST was detected using mouse anti-GST (SAB4200237-200UL, Sigma-Aldrich, Germany, 1:7500 dilution) were used. For viral proteins, viral supernatant was centrifuged through 20% sucrose gradient for a minimum of 4 hrs at 4°C, 14.800 rpm. The supernatant was discarded, and the viral pellet was lysed using RIPA buffer for 5 min followed by denaturation at 95°C in Roti-load sample buffer for 5 min and SDS PAGE using anti-p24 antibody (NIH).

Modeling of HIV-1 capsid variants. The structural model of the HIV-1 M capsid and CYPA generated by TopModel (44, 45) taken from (43). The capsid-CYPA complex was formed by superimposing the structures of the components onto the proteins of the cryo-EM structure PDB ID 5FJB. Mutations at the CYPA binding loop to HIV-1 N, HIV-1 O, and the HIV-1 M A88V, M91L, and H87P variants were introduced with SCWRL (46). HIV-1 N P87H and I91L monomers were modeled with (47). The capsid-CYPA complex was formed as above. PDB2PQR (48) was used to determine the protonation state at pH = 7.4 with the help of PROPKA 3 (49). The systems were packed using PACKMOL-Memgen (46) adding KCl in a concentration of 0.15 M and using a minimum distance between the protein(s) and the edges of the water box of 15.0 Å. The ff19SB force field (44) was used for the proteins, the OPC force field (50) with the corresponding Li/Merz ion parameters (49) was used for water and ions, respectively.

Thermalization, density adjustment, and dihedral modification for PMF calculations. Thermalization and density adjustment were carried out using pmemd from the Amber22 software package (51, 52) with a time step of 2 fs. The Langevin thermostat (53) and Berendsen barostat (44) were used for temperature and pressure control, respectively. For the treatment of long-range electrostatic interactions, the Particle Mesh Ewald method (54) was used with a direct-space non-bonded cutoff of 9.0 Å. The SHAKE algorithm was used to constrain bond lengths involving hydrogen atoms (55). For each loop variant (HIV-1 M, HIV-1 N, HIV-1 O, HIV-1 M A88V), the loop either binding to CYPA or unbound was turned at the ω dihedral between G89 and P90 in 3° steps, which leads to 121 windows for each setup. The dihedral was modified to the target value during 10.000 steps of relaxing the system with the steepest decent algorithm followed by 10.000 steps with the conjugate gradient algorithm applying a force at the ω dihedral of 200 kcal mol⁻¹ rad⁻². During 10 ns, the system was heated to 300 K and 1 bar under NPT conditions.

Umbrella sampling and PMF calculations. For each window, 20 ns of umbrella sampling simulations in the NPT ensemble were performed, using a harmonic restraining potential with a force constant of 200 kcal · mol⁻¹ rad⁻² and writing out the ω dihedral every 50 simulation steps. The ω dihedral distribution was analyzed with the Weighted Histogram Analysis Method (WHAM) v2.0.9.1 (48). The periodicity was considered in the analysis, histogram limits were set to -0.5° and 360.5° for 722 bins in total, and the tolerance was set to 10⁻⁷ kcal

mol⁻¹. The histograms showed a median overlap of 25% between contiguous windows (Figures S4 –S11, Table S1), well suited for PMF calculations (56).

The error along the PMF ($G(x)$) was estimated by block averaging; for each system, the data were separated into five parts of 4 ns each. The squared error in the estimate of the mean position of ω in window i ($\text{var}(\bar{x}_i)$) was calculated based on the block averages (for further details see SI and eq. S1) (57). From there, the error was propagated to derive the variance of PMFs ($\text{var}[G(x)]$) taking into account $\text{var}(\bar{x}_i)$ as well as the used force constant (k), the sampling step size ($\Delta\omega$), and the starting position (ω_0) as suggested by Zhu and Hummer (eq. 1) (54).

$$\text{var}[G(x)] \approx (k\Delta)^2 \sum_{i=1}^{\frac{(x-\omega_0)}{\Delta}} \text{var}(\bar{x}_i) \quad \text{eq. 1}$$

From $\text{var}[G(x)]$, the standard deviation and the standard error of the mean were computed. For error propagation when subtracting values of windows n and m , e.g., for obtaining $\Delta G_{t \rightarrow c}^\#$, SEM was calculated according to eq. 2:

$$SEM = \sqrt{SEM_m^2 + SEM_n^2} \quad \text{eq. 2}$$

Individual states, e.g., *cis* ($\omega = 0^\circ$), *trans* ($\omega = 180^\circ$), and transition state ($\omega = 90^\circ$), were visually checked, and figures were prepared with PyMOL.

Results

Construction of non-M HIV and SIVgor reporter viruses.

We constructed novel nanoluciferase-based reporter viruses for HIV-1 N, HIV-1 O, HIV-1 P, and SIVgor. *Nanoluciferase* was cloned in replacement of *nef* genes. In addition, two stop codons were inserted in the *env* genes. Production of VSV-G-pseudotyped viral particles was done through transfection of HEK293T cells, and such virions were tested on human HeLa cells, for infectivity by nanoluciferase measurement, two days after infection (data not shown). We also constructed pMDLg/pRRE-based *gag-pol* constructs for HIV-1 N, HIV-1 O, HIV-1 P and SIVgor. Such constructs were made by replacing HIV-1 M *gag-pol* in pMDLg/pRRE with non-M or SIVgor *gag-pol*.

Non-M HIVs are inhibited by human TRIM5 α in human cells.

To test whether the replication of non-pandemic HIVs is restricted by human TRIM5 α , equal amounts of reporter viruses of non-M HIVs (HIV-1 N, HIV-1 O, HIV-1 P) and SIVs (SIVcpzPtt, SIVcpzPts, SIVgor) were used for infections of human wildtype (WT) U-87 MG and huTRIM5 α knockout (KO) U-87 MG cells (37) (Fig. 1A). In addition, we included reporter viruses for HIV-1 M and for the equine infectious anemia virus (EIAV); EIAV is known to be sensitive to human TRIM5 α (19). While the infectivity of HIV-1 M was equal in WT and TRIM5 KO cells, infection by non-M HIVs but also SIVgor was enhanced when huTRIM5 α was knocked down (Fig. 1B, Fig. S1A). Infection by HIV-1 N increased to up to three folds in the huTRIM5 α KO cells as compared to control cells, infection by HIV-1 O, HIV-1 P, and SIVgor reached 2.5-, 3.5-, and 2-folds, respectively in the absence of huTRIM5 α , suggesting inhibition of these viruses by human TRIM5 α . EIAV showed 6.5-fold higher infectivity in the absence of huTRIM5 α , compared to WT cells. In contrast, SIVcpzPtt and SIVcpzPts did not benefit from the absence of huTRIM5 α (Fig. 1B),

as described before (58). We also compared infection of WT U-87 MG cells with HIV-1 M vs. non-M HIV-1s virions produced by their respective *gag-pol* expression plasmids and confirmed a strongly reduced infectivity of HIV-1 N, O and P compared to the infectivity of HIV-1 M (Fig. S1B). The restriction of non-pandemic HIV-1s was seen over a wide range of virus input in WT U87-MG cells and in primary human macrophages (Fig. S2).

Capsid and its CYPA binding loop mediate differences in sensitivity to huTRIM5 α .

Since TRIM5 α is a capsid-binding factor (11), we opted to investigate on the mechanisms behind differences in sensitivity to huTRIM5 α between HIV-1 M and non-pandemic HIVs. We transferred the capsid encoding sequence from HIV-1 N, HIV-1 O, HIV-1 P, to HIV-1 M in the *gag-pol* expression construct pMDLg/pRRE representing HIV-1 M sequence (Fig. 1C). In contrast to WT HIV-1 M, chimeric viruses with capsid from non-M viruses were inhibited 2.5 – 8-fold in WT cells compared to huTRIM5 α KO cells (Fig. 1D), confirming the role of viral capsid for restriction by human TRIM5 α .

Reports have described that in human cells the capsid-interacting cellular protein cyclophilin A (CYPA) protects HIV-1 M against the antiviral activity of huTRIM5 α (20, 21). In capsid, CYPA binds to a loop between helix 4 and helix 5, termed CYPA binding loop. Here CYPA directly interacts with residues G89 and P90 (23), which are conserved in pandemic and non-pandemic HIVs. However, other residues between these viruses show variations, HIV-1 N, and HIV-1 P share an identical CYPA binding loop (Fig. 1E, Fig. S3). To explore the impact of loop variability, we swapped in capsid the CYPA binding loops between HIV-1 M, HIV-1 N, and HIV-1 O. Thus, we created HIV-1 M *gag-pol* constructs with a CYPA binding loop of HIV-1 N (identical to HIV-1 P) or HIV-1 O. In reverse, we transferred the HIV-1 M CYPA binding loop to HIV-1 N or HIV-1 O *gag-pol* constructs. Stunningly, viruses that had the CYPA binding loop of non-pandemic HIVs showed a restriction in WT cells compared to TRIM5 α KO cells, and non-pandemic viruses with a CYPA binding loop of HIV-1 M escaped the restriction by TRIM5 α (Fig. 1F). These findings demonstrated that the capsid CYPA binding loops account for differences in infection levels of pandemic and non-pandemic HIVs in huTRIM5 α expressing cells.

Capsid residue at position 88 mediates HIV sensitivity to huTRIM5 α .

In the capsid CYPA binding loop, the human CYPA protein binds strongly to residues G89 and P90 (23) but also A88 binds in the active site groove of CYPA (59). We hypothesized that variability in residue 88 in the CYPA binding loops could explain our observations regarding the differential sensitivity of HIV-1 M and the non-pandemic HIV-1s to TRIM5 α . We infected both WT and TRIM5 α KO cells with reporter viruses that had mutations in the CYPA binding loop at position 88, HIV-1 M A88V, HIV-1 N V88A, HIV-1 O M88A or HIV-1 P V88A, and compared their infectivity to the corresponding WT viruses. For HIV-1 M, we included the well-characterized HIV-1 M G89V and A88V-G89V capsid mutants, which do not bind CYPA. As expected, both mutations in HIV-1 M, A88V and G89V were strongly inhibited in WT U-87 MG cells compared to WT virus (Fig. 2A). However, in TRIM5 α KO cells infections by both capsid mutants were not reduced compared to WT HIV-1 M, with infection by the A88V mutant even 4.3-fold higher than infection by WT virus (Fig. 2B, Fig. S4A, B). Infections by capsid mutants of non-pandemic HIVs showed a contrasting pattern. In WT cells, the infectivity of HIV-1 N V88A was 5-fold higher, of HIV-1 O M88A was 2.3 folds higher, and of HIV-1 P V88A was 2.1 folds higher than infections by their WT viruses (Fig. 2C). However, these capsid mutants of non-pandemic viruses had a similar infectivity to WT virus in TRIM5 α KO cells (Fig. 2D). To further analyze if other residues in the CYPA binding loop could inhibit the protection in HIV-1 M or induce a

resistance to TRIM5 α in HIV-1 N, additional mutations were tested (Fig. S5). As a positive control, we included the A92E change in HIV-1 M and the P92E mutation in HIV-1 N. As it was shown that the Ala 92 to Glu mutation disrupts the binding of human TRIM5 α to HIV-1 M viral cores (20). In HIV-1 M, the mutations H87P, I91L, and A92E, in contrast to A88V or G89V did not enhance the sensitivity to TRIM5 α (Fig S5A). In HIV-1 N, however, the reverse mutations P87H, L91I, or P92E, similar to V88A induced a protection against TRIM5 α (Fig. S5B). Together, these findings show that residue 88 in the CYPA binding loop of capsid is a unique determinant of TRIM5 α restriction in pandemic and non-pandemic HIV-1. Other CYPA loop residues in non-pandemic HIV-1 may be additionally important.

Pandemic and non-pandemic HIV-1 capsids bind CYPA.

With the observed differences in capsid CYPA loop between M and non-M HIV-1s (Fig. 1F), we wanted to test whether all four viruses interact with CYPA similarly. Using a GST-tagged CYPA, we assessed CYPA-capsid interaction in pulldown experiments. Immunoblots of these precipitations found similar levels of capsid protein for all four HIV-1s (Fig. 2E). In addition, we found that CYPA is packaged in virions of pandemic and non-pandemic HIV-1s (Fig. 2F). To understand if these viruses package similarly CYPA, we exposed them to increasing amounts of cyclosporine A (CsA), a drug that binds CYPA and prevents CYPA interaction with capsid. The dose-dependent reduction of CYPA packaging showed a small difference between HIV-1 M and the non-pandemic HIV-1s. A CsA dose of 1 μ M reduced virion-associated CYPA by around 70% in the context of non-M HIVs, as opposed to only 40% by HIV-1 M, possibly suggesting differences in CYPA binding strength between capsids of these viruses (Figs. 2F, G).

Cyclophilin A decreases the isomerization barrier the most for HIV-1 M wild type and variants that are protected against TRIM5 α .

To address the question if the binding of CYPA to HIV-1 capsid has different effects between the pandemic HIV-1 M *versus* HIV-1 N, HIV-1 O, HIV-1 P, or variants of HIV-1 types, we performed potential of mean-force (PMF) computations of the isomerization reaction catalyzed by CYPA. HIV-1 P was not considered because the loop composition is as in HIV-1 N. The isomerization occurs between the *trans* and *cis* conformations of the peptide bond formed by residues G89 and P90 in the CYPA binding loop of the capsid (36). The conformational change is characterized by the torsion angle ω (*trans*: $\omega = 180^\circ$, *cis*: $\omega = 0^\circ$; Figs. 3A, B). The PMF is the free energy change during the isomerization evaluated along the reaction coordinate ω (Fig. 3C); the PMF describes an average over the conformations of the surrounding protein residues and solvent molecules, such that the effect of other CYPA binding loop residues that vary among different HIV-1 clades is considered.

We computed PMFs of the isomerization in the presence and absence of CYPA and calculated the free energy difference $\Delta G_{t,c}$ as the difference between the PMF values for the *trans* and *cis* conformations (Fig. S5, Table S2, Fig. 3D) as well as the barrier height $\Delta G_{t \rightarrow c}^\#$ as the difference between the PMF values for the *trans* conformation and the maximal value at $\omega \approx 90^\circ$ (Fig. S5, Table S3, Fig. 3D).

In the absence of CYPA, $\Delta G_{t,c} \approx 1.7$ to 2.3 kcal mol $^{-1}$ for the WT systems (Fig. S6, Table S2), indicating that the *trans* conformation of the peptide bond between residues G89 and P90 is preferred over the *cis* conformation by $\sim 95 : 5$ in line with NMR experiments (36). This indicates that the energetic description of the states at the minima is appropriate, confirming previous work (60).

In the presence of CYPA, the barrier height $\Delta G^{\#}_{t \rightarrow c}$ decreases in all WT systems by 1.7 – 2.9 kcal mol⁻¹ compared to the absence of CYPA (Fig. 3D, Fig. S6, Table S3), indicating a faster isomerization when catalyzed by CYPA, as expected. The decrease of $\Delta G^{\#}_{t \rightarrow c}$ is the largest for HIV-1 M, indicating that the isomerization is most accelerated by CYPA for HIV-1 M, which is protected against TRIM5 α (Fig. 1), and that it is ~5-10 fold faster for HIV-1 M than for the other WT systems, which are not protected (Fig. 1).

As to variants, HIV-1 M A88V is not protected, and its behavior differs from the WT in the presence of CYPA: The *trans* conformation is more favorable, and the isomerization barrier is comparable to that in solution (Fig. S6, Tables S2 and S3). This may be caused by V88 sticking into the hydrophobic surface of CYPA, which hampers the isomerization (Fig. S7). Notably, variants HIV-1 N L91I and P87H, which become protected against TRIM5 α in contrast to the WT (Fig. S5B), show decreases in $\Delta G^{\#}_{t \rightarrow c}$ in the presence of CYPA that are as large as or comparable to that in HIV-1 M. The reverse mutation in HIV-1 M, I91L, keeps the variant protected (Fig. S5A) and, analogously, the decrease in $\Delta G^{\#}_{t \rightarrow c}$ is the fourth largest.

Overall, the magnitude of the decrease in $\Delta G^{\#}_{t \rightarrow c}$ in the presence of CYPA allows for an almost perfect ordering of the investigated HIV-1 types and variants, with protected ones showing generally the largest decreases (Fig. 3D). The change in $\Delta G_{t,c}$ would not allow such an ordering. Although the quantitative relation of barrier heights derived from PMFs to kinetics requires caution (61), this finding suggests that the kinetics of the *trans/cis* isomerization plays a decisive role in the protective effect of CYPA for HIV-1 M.

Rhesus TRIMCyp inhibits non-M HIVs.

TRIMCyp proteins differentially halt retroviral infection through the binding of their CYPA domain to capsid CYPA binding loop, early during infection, this inhibition can be blocked by cell treatment with CsA (26). For instance, owl monkey TRIMCyp is active against HIV-1 but not HIV-2 and rhTRIMCyp from rhesus macaques (rh) inhibits HIV-2 but not HIV-1 M (18, 41). In rhTRIMCyp, CYPA differs from human CYPA by two residues, the CYPA in rhTRIMCyp has N66 and H69 while human CYPA has D66 and R69 (62). It was shown that HIV-1 M's resistance and HIV-1 O's inhibition by rhTRIMCyp were due to the presence of N66 and H69 in this CYPA domain (59). To further understand if rhTRIMCyp or a variant in which we reversed the two residues to D66 and R69 have differential antiviral activity to pandemic and non-pandemic HIV-1, we generated cell lines expressing WT rhTRIMCyp or its CYPA mutants N66D, H69R, N66D-H69H (Fig. 4A). We challenged such cells with HIV-1 M, HIV-1 N, HIV-1 O, HIV-1 P and SIVgor. As expected, rhTRIMCyp did not reduce the infectivity of HIV-1 M, but strongly inhibited HIV-1 O (58). In addition, all other viruses, HIV-1 N, HIV-1 P, SIVgor were also strongly inhibited in cells expressing rhTRIMCyp by or more than 90% (Figs. 4B, C and Fig. S8). TRIMCyp with a human identical CYPA domain (N66D H69R, DR), recognized pandemic and non-pandemic viruses and displayed strong antiviral activity, further indicating that human CYPA interacts with all tested viruses. Mutating only residue H69R (NR) in rhTRIMCyp caused a complete loss of antiviral activity against HIV-1 N and HIV-1 O, in addition to remaining inactive against HIV-1 M. However, HIV-1 P and SIVgor were still inhibited by around 50%. In contrast, mutating N66 to the human D in rhTRIMCyp (DH mutant), generated an antiviral protein that inhibited efficiently all viruses (Figs. 4B, C and Fig. S8). Previous data suggested that capsid residue 88 in the CYPA binding loop mediates differential interaction of HIV-1 M and O with rhTRIMCyp (59). The mutations in residue 88 reversed the resistance of HIV-1 M and the sensitivity of HIV-1 N, HIV-1 O and HIV-1 P to rhTRIMCyp (Figs. 4B, C). The non-pandemic HIVs with capsid mutations at position 88 were still sensitive to antiviral activity of TRIMCyp.DR, as

was HIV-1 M A88V (Fig. 4B). The HIV-1 M G89V, was predictably not inhibited by any TRIMCyp protein, likely because the G89V mutation prevented the interaction of TRIMCyp (Fig. 4B). These data suggest that the human CYPA domain in TRIMCyp proteins and likely free CYPA can recognize the incoming viral cores of non-pandemic HIV-1s.

Pandemic and non-pandemic HIVs show different dependencies on CYPA.

To test whether the depletion of CYPA affects pandemic and non-pandemic HIVs differently, a CYPA knockdown in U-87 MG cells and huTRIM5 α KO U-87 MG using the CRISPR/Cas9 system was done (Fig. 5A). CYPA knockdown in WT cells was associated with a strong and significant inhibition of HIV-1 M infectivity by up to 86%, and while the TRIM5 α KO generated infections comparable to WT cells, the cells that lost TRIM5 α and additionally CYPA expression were unexpectedly less infectable than WT or TRIM5 α KO cells, suggesting that CYPA function for HIV-1 M is beyond protection against TRIM5 α (Fig. 5B). Non-M HIVs and SIVgor were also tested in such conditions. The CYPA KD affected the non-pandemic HIVs less than HIV-1 M and caused only 50% inhibition. In further contrast to HIV-1 M, cells with no TRIM5 α and no CYPA were much better infectable than the TRIM5 α KO cells by the non-pandemic HIV-1s (Figs. 5C, E). Infection with SIVgor differed from all HIV-1s and was not affected by CYPA KD in WT or TRIM5 α KO cells, demonstrating that the CYPA KD did not impair cell vitality (Fig. S9A).

In an additional approach, we tested CsA treatment of cells in infection experiments. Increasing levels of CsA (0.1 μ M to 10 μ M) inhibited up to 91% of infection by HIV-1 M in WT U87 MG cells (Fig. 5F). In WT cells treated with 1 μ M CsA, HIV-1 N was inhibited by 41%, HIV-1 O by 57%, HIV-1 P by 66%, while HIV-1 M's infectivity was decreased by 74%. Interestingly, high CsA concentrations had no further effect on infections by HIV-1 N and HIV-1 O but inhibited 77% of HIV-1 P (Fig. 5F). As expected, SIVgor did not react to CsA treatment of WT U-87 MG cells (Fig. S9B). Predictable, in CYPA-depleted cells, CsA treatment lost almost all its antiviral activity and only HIV-1 M showed some mild inhibition using 10 μ M CsA (Fig. 5G). In TRIM5 α KO cells, CsA treatment inhibited only HIV-1 M but had no effect on non-M HIVs, mirroring data obtained with CYPA KD (Fig. 5H). In CYPA and TRIM5 α double depleted cells, CsA had no significant inhibitory activity against any virus tested, suggesting that CsA itself does inhibit these viruses (Fig. 5I, Fig. S9B). Together, these data suggest that the non-pandemic HIV-1s have a weak and partial protection against TRIM5 α by its CYPA binding.

Discussion

The reason(s) why non-M HIVs did not extensively spread in the human population remain(s) elusive. Some reports have pointed out differences in GAG capsid sequences but also differences in the functional activity of viral accessory proteins (63, 64). Here, we found that non-pandemic HIV-1 are subject to restriction by human TRIM5 α . While it was shown that CYPA forms a protective layer around the viral core of HIV-1 M to prevent destruction by human TRIM5 α (20, 21), the CYPA interaction with non-pandemic HIV-1 N, O and P does not protect strongly against TRIM5 α .

Our data demonstrate that the non-pandemic HIV-1s interact with and bind CYPA to a level that appears similar to the level of binding of HIV-1 M. Surprisingly, our findings show that the viral capsid CYPA binding loop determines the different sensitivities to TRIM5 α of HIV-1 M and the non-pandemic HIV-1s. A recent report (65) has suggested capsid residues, such as residue at position 50, as important for differential sensitivity to TRIM5 α by HIVs. Our findings suggest that more than one region of the capsid is involved in the regulation of TRIM5 α activity. Thus, we postulate that not the binding of CYPA itself, but the nature of

CYPA capsid interaction is a regulator of TRIM5 α sensitivity. Despite an identical GP motif in capsid CYPA binding loops in pandemic and non-pandemic HIV-1s, these viruses engage CYPA differently, suggesting an important role from other residues of the CYPA binding loop.

Moreover, a rescue of infection of non M HIV-1s, when their capsids were specifically mutated at position 88 or when the CYPA domain of rhTRIMCyp was mutated at position 66 or 69, shows the importance of the capsid CYPA binding loop for such restriction by rhTRIMCyp, as previously shown for HIV-1 M, HIV-1 O, and HIV-2 (18, 59). It is possible that the presence of valine (HIV-1 N and HIV-1 P capsid) or methionine for HIV-1 O at position 88 of the capsid, as opposed to alanine in the HIV-1 M, changes capsid conformation and allows availability of the loop to other host factors like TRIM5 α , in addition to CYPA binding. This may restrict non-M HIVs by TRIM5 α , but this hypothesis will need clarification.

Based on our study results, we postulated that the CYPA *trans/cis* isomerization activity on the capsid G89-P90 peptide bond (36, 61) differs between HIV-1 M and non-pandemic HIVs and that this difference changes the binding strength of TRIM5 α in an unknown way that may involve allostery (35). This hypothesis is supported by the PMF computations of the isomerization reaction. The capsid binding sites for TRIM5 α are still ill-defined, although it is known that the binding involves the capsid CYPA binding loop (13). In crystal structures, the loop of HIV-1 M is in the *trans* conformation in the presence of CYPA, whereas the loop in HIV-1 O is in the *cis* conformation in the presence of CYPA (61). It is not known which of the conformations is preferred under native conditions. However, TRIM5 α should bind neither too strongly nor too weakly to the HIV-1 capsid to build an antiviral scaffold around the core (66). Considering that in G-P peptides the *trans* conformation prevails according to crystal structure (67) and NMR spectroscopy (68) analyses, our results lead us to speculate that a faster isomerization process might lead to reaching a higher proportion of *cis* conformation faster in the CYPA binding loop, which might affect TRIM5 α binding. This would be most relevant for HIV-1 M. In turn, and, in line with this, in the HIV-1 M A88V capsid mutant in the presence of CYPA, the isomerization barrier remains unchanged and almost as high as in the other HIV-1 WT in solution, which might explain why this variant does not show resistance against TRIM5 α anymore. This would also explain why non-M HIV-1s with valine or methionine are also inhibited by TRIM5 α . The magnitude of the decrease in the isomerization barrier in the presence of CYPA allows for an almost perfect ordering of all HIV-1 types and variants investigated in PMF computations, with protected ones showing generally the largest decreases, suggesting that the kinetics of the *trans/cis* isomerization plays a decisive role in the protective effect of CYPA for HIV-1 M.

The non-pandemic HIV-1s likely face several restrictions in human cells that slow a rapid adaptation. Ala88 is conserved in different HIV-1 M isolates, and Val in the few cases of HIV-1 N and HIV-1 P. However, HIV-1 O isolates show more variability and there are viruses that have at position 88 Val, Met, or Ile (Fig. S3). SIVgor, the ancestor virus of HIV-1 O and HIV-1 P has also Val at position 88 and shows similar restriction by human TRIM5 α (Fig. S1). SIVcpz is escaping human TRIM5 α likely by its A88. Therefore, the generation of HIV-1 M was not restricted by human TRIM5 α . It is, however, puzzling to understand why in the generation of HIV-1 N the A88 changed to V88. As we show in Figs. 2B and S4, HIV-1 M with an A88V mutation has higher infectivity in cells lacking TRIM5 α compared to WT virus. Thus, HIV-1 N may have evolved in an environment with reduced antiviral TRIM5 α activity.

ACKNOWLEDGEMENTS

We thank Wioletta Hörschken, Björn Wefers, and Yvonne Dickschen for excellent technical assistance. We thank Thomas Gramberg, Beatrice H. Hahn, Frank Kirchhoff, Michael Malim, Daniel Sauter, Heiner Schaal, Jonathan P. Stoye, Greg Towers, and Stephen R. Yant for reagents. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: psPAX2 (Cat# 11348) from Didier Trono, SIVcpz TAN1.910 infectious molecular clone (Cat #11496) and SIVgorCP2139 (Cat # ARP-11722) from Jun Takehisa, Matthias H. Kraus and Beatrice H. Hahn. APT is supported by German Academic Exchange Service (DAAD), SL is supported by Chinese Government Scholarship, CM is supported by the Heinz-Ansman foundation for AIDS research. This work was, in part, supported by Deutsche Forschungsgemeinschaft (DFG) through GRK 2158/2 (project number 270650915) to HG. HG is grateful for computational support and infrastructure provided by the “Zentrum für Informations- und Medientechnologie” (ZIM) at the Heinrich-Heine-University Düsseldorf and the computing time provided by the John von Neumann Institute for Computing (NIC) to HG on the supercomputer JUWELS at Jülich Supercomputing Centre (JSC) (user ID: VSK33).

References

1. P. M. Sharp, B. H. Hahn, Origins of HIV and the AIDS Pandemic. *Cold Spring Harb Perspect Med* **1**, a006841 (2011).
2. S. Bush, D. M. Tebit, HIV-1 group O origin, evolution, pathogenesis, and treatment: Unraveling the complexity of an outlier 25 years later. *AIDS Rev* **17**, 147–158 (2015).
3. S. M. Bell, T. Bedford, Modern-day SIV viral diversity generated by extensive recombination and cross-species transmission. *PLoS Pathog* **13**, e1006466 (2017).
4. A. P. Twizerimana, R. Scheck, D. Häussinger, C. Münk, Post-entry restriction factors of SIVcpz. *Future Virol* **13**, 727–745 (2018).
5. R. S. Harris, J. F. Hultquist, D. T. Evans, The Restriction Factors of Human Immunodeficiency Virus. *Journal of Biological Chemistry* **287**, 40875–40883 (2012).
6. M. H. Malim, P. D. Bieniasz, HIV Restriction Factors and Mechanisms of Evasion. *Cold Spring Harb Perspect Med* **2**, a006940 (2012).
7. P. Staeheli, O. Haller, Human MX2/MxB: a Potent Interferon-Induced Postentry Inhibitor of Herpesviruses and HIV-1. *J Virol* **92** (2018).
8. G. Boso, C. A. Kozak, Retroviral Restriction Factors and Their Viral Targets: Restriction Strategies and Evolutionary Adaptations. *Microorganisms* **8** (2020).
9. L. Cano-Ortiz, T. Luedde, C. Münk, HIV-1 restriction by SERINC5. *Med Microbiol Immunol* **212**, 133–140 (2023).
10. A. Reymond, *et al.*, The tripartite motif family identifies cell compartments. *EMBO J* **20**, 2140–51 (2001).
11. B. K. Ganser-Pornillos, O. Pornillos, Restriction of HIV-1 and other retroviruses by TRIM5. *Nat Rev Microbiol* **17**, 546–556 (2019).
12. S. B. Kutluay, D. Perez-Caballero, P. D. Bieniasz, Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection. *PLoS Pathog* **9**, e1003214 (2013).
13. H. Yang, *et al.*, Structural insight into HIV-1 capsid recognition by rhesus TRIM5 α . *Proc Natl Acad Sci U S A* **109**, 18372–7 (2012).
14. T. Pertel, *et al.*, TRIM5 is an innate immune sensor for the retrovirus capsid lattice <https://doi.org/10.1038/nature09976> (February 25, 2018).

- 565 15. D. M. Sayah, E. Sokolskaja, L. Berthou, J. Luban, Cyclophilin A retrotransposition
566 into TRIM5 explains owl monkey resistance to HIV-1. *Nature* **430**, 569–573 (2004).
- 567 16. G. Brennan, Y. Kozyrev, S.-L. Hu, TRIMCyp expression in Old World primates
568 *Macaca nemestrina* and *Macaca fascicularis*. *Proceedings of the National Academy of*
569 *Sciences* **105**, 3569–3574 (2008).
- 570 17. S. Sebastian, J. Luban, TRIM5alpha selectively binds a restriction-sensitive retroviral
571 capsid. *Retrovirology* **2**, 40 (2005).
- 572 18. E. E. Nakayama, T. Shioda, TRIM5α and species tropism of HIV/SIV. *Front*
573 *Microbiol* **3**, 1–12 (2012).
- 574 19. D. T. Saenz, W. Teo, J. C. Olsen, E. M. Poeschla, Restriction of feline
575 immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. *J Virol* **79**,
576 15175–88 (2005).
- 577 20. A. Selyutina, *et al.*, Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by
578 Blocking Human TRIM5α Binding to the Viral Core. *Cell Rep* **30**, 3766–3777.e6
579 (2020).
- 580 21. K. Kim, *et al.*, Cyclophilin A protects HIV-1 from restriction by human TRIM5α. *Nat*
581 *Microbiol* **4**, 2044–2051 (2019).
- 582 22. B. K. Ganser, S. Li, V. Y. Klishko, J. T. Finch, W. I. Sundquist, Assembly and
583 Analysis of Conical Models for the HIV-1 Core. *Science (1979)* **283**, 80–83 (1999).
- 584 23. S. Yoo, *et al.*, Molecular recognition in the HIV-1 capsid/cyclophilin A complex. *J*
585 *Mol Biol* **269**, 780–795 (1997).
- 586 24. M. E. C. Caines, *et al.*, Diverse HIV viruses are targeted by a conformationally
587 dynamic antiviral. *Nat Struct Mol Biol* **19**, 411–416 (2012).
- 588 25. T. R. Gamble, *et al.*, Crystal structure of human cyclophilin A bound to the amino-
589 terminal domain of HIV-1 capsid. *Cell* **87**, 1285–1294 (1996).
- 590 26. G. J. Towers, *et al.*, Cyclophilin A modulates the sensitivity of HIV-1 to host
591 restriction factors. *Nat Med* **9**, 1138–1143 (2003).
- 592 27. E. Toccafondi, D. Lener, M. Negroni, HIV-1 Capsid Core: A Bullet to the Heart of the
593 Target Cell. *Front Microbiol* **12**, 755 (2021).
- 594 28. N. A. Kootstra, C. Münk, N. Tonnu, N. R. Landau, I. M. Verma, Abrogation of
595 postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.
596 *Proceedings of the National Academy of Sciences* **100**, 1298–1303 (2003).
- 597 29. E. K. Franke, H. E. H. Yuan, J. Luban, Specific incorporation of cyclophilin a into
598 HIV-1 virions. *Nature* **372**, 359–362 (1994).
- 599 30. M. Thali, *et al.*, Functional association of cyclophilin A with HIV-1 virions. *Nature*
600 **372**, 363–365 (1994).
- 601 31. W. Peng, *et al.*, Functional analysis of the secondary HIV-1 capsid binding site in the
602 host protein cyclophilin A. *Retrovirology* **16**, 10 (2019).
- 603 32. Z. Ambrose, *et al.*, Human immunodeficiency virus type 1 capsid mutation N74D
604 alters cyclophilin A dependence and impairs macrophage infection. *J Virol* **86**, 4708–
605 14 (2012).
- 606 33. J. Shi, J. Zhou, V. B. Shah, C. Aiken, K. Whitby, Small-molecule inhibition of human
607 immunodeficiency virus type 1 infection by virus capsid destabilization. *J Virol* **85**,
608 542–9 (2011).
- 609 34. T. Schaller, *et al.*, HIV-1 capsid-cyclophilin interactions determine nuclear import
610 pathway, integration targeting and replication efficiency. *PLoS Pathog* **7**, e1002439
611 (2011).
- 612 35. M. Lu, *et al.*, Dynamic allostery governs cyclophilin A–HIV capsid interplay.
613 *Proceedings of the National Academy of Sciences* **112**, 14617–14622 (2015).

- 614 36. D. A. Bosco, E. Z. Eisenmesser, S. Pochapsky, W. I. Sundquist, D. Kern, Catalysis of
615 cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. *Proceedings of*
616 *the National Academy of Sciences* **99**, 5247–5252 (2002).
- 617 37. J. M. Jimenez-Guardeño, L. Apolonia, G. Betancor, M. H. Malim, Immunoproteasome
618 activation enables human TRIM5 α restriction of HIV-1. *Nat Microbiol* **4**, 933–940
619 (2019).
- 620 38. J. Takehisa, *et al.*, Generation of infectious molecular clones of simian
621 immunodeficiency virus from fecal consensus sequences of wild chimpanzees. *J Virol*
622 **81**, 7463–75 (2007).
- 623 39. M. Bock, K. N. Bishop, G. Towers, J. P. Stoye, Use of a Transient Assay for Studying
624 the Genetic Determinants of FvI Restriction. *J Virol* **74**, 7422–7430 (2000).
- 625 40. T. Dull, *et al.*, A third-generation lentivirus vector with a conditional packaging
626 system. *J Virol* **72**, 8463–71 (1998).
- 627 41. S. J. Wilson, *et al.*, Independent evolution of an antiviral TRIMCyp in rhesus
628 macaques. *Proc Natl Acad Sci U S A* **105**, 3557–62 (2008).
- 629 42. J. Vermeire, *et al.*, Quantification of reverse transcriptase activity by real-time PCR as
630 a fast and accurate method for titration of HIV, lenti- and retroviral vectors. *PLoS One*
631 **7**, e50859 (2012).
- 632 43. A. P. Twizerimana, *et al.*, Cell Type-Dependent Escape of Capsid Inhibitors by Simian
633 Immunodeficiency Virus SIVcpz. *J Virol* **94** (2020).
- 634 44. P. Li, L. F. Song, K. M. Merz, Systematic Parameterization of Monovalent Ions
635 Employing the Nonbonded Model. *J Chem Theory Comput* **11**, 1645–1657 (2015).
- 636 45. D. Mulnaes, *et al.*, TopModel: Template-Based Protein Structure Prediction at Low
637 Sequence Identity Using Top-Down Consensus and Deep Neural Networks. *J Chem*
638 *Theory Comput* **16**, 1953–1967 (2020).
- 639 46. G. G. Krivov, M. V. Shapovalov, R. L. Dunbrack, Improved prediction of protein side-
640 chain conformations with SCWRL4. *Proteins* **77**, 778–95 (2009).
- 641 47. J. Jumper, *et al.*, Highly accurate protein structure prediction with AlphaFold. *Nature*
642 **596**, 583–589 (2021).
- 643 48. H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, A. DiNola, J. R. Haak,
644 Molecular dynamics with coupling to an external bath. *J Chem Phys* **81**, 3684–3690
645 (1984).
- 646 49. M. H. M. Olsson, C. R. Søndergaard, M. Rostkowski, J. H. Jensen, PROPKA3:
647 Consistent Treatment of Internal and Surface Residues in Empirical p K_a Predictions.
648 *J Chem Theory Comput* **7**, 525–537 (2011).
- 649 50. S. Schott-Verdugo, H. Gohlke, PACKMOL-Memgen: A Simple-To-Use, Generalized
650 Workflow for Membrane-Protein-Lipid-Bilayer System Building. *J Chem Inf Model*
651 **59**, 2522–2528 (2019).
- 652 51. C. Tian, *et al.*, ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained
653 against Quantum Mechanics Energy Surfaces in Solution. *J Chem Theory Comput* **16**,
654 528–552 (2020).
- 655 52. D. A. Case Ross C Walker UC San Diego, A. E. Thomas Cheatham, “Amber 2022
656 Reference Manual Principal contributors to the current codes” (April 16, 2023).
- 657 53. S. Izadi, R. Anandakrishnan, A. V. Onufriev, Building Water Models: A Different
658 Approach. *J Phys Chem Lett* **5**, 3863–3871 (2014).
- 659 54. F. Zhu, G. Hummer, Convergence and error estimation in free energy calculations
660 using the weighted histogram analysis method. *J Comput Chem* **33**, 453–465 (2012).
- 661 55. D. Quigley, M. I. J. Probert, Langevin dynamics in constant pressure extended
662 systems. *J Chem Phys* **120**, 11432–11441 (2004).

56. J.-P. Ryckaert, G. Ciccotti, H. J. C. Berendsen, Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *J Comput Phys* **23**, 327–341 (1977).
57. A. Grossfield, “An implementation of WHAM: the Weighted Histogram Analysis Method Version 2.0.10” (March 9, 2023).
58. Z. Kratovac, *et al.*, Primate Lentivirus Capsid Sensitivity to TRIM5 Proteins. *J Virol* **82**, 6772–6777 (2008).
59. A. J. Price, *et al.*, Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. *Nat Struct Mol Biol* **16**, 1036–1042 (2009).
60. U. Doshi, D. Hamelberg, Reoptimization of the AMBER Force Field Parameters for Peptide Bond (Omega) Torsions Using Accelerated Molecular Dynamics. *J Phys Chem B* **113**, 16590–16595 (2009).
61. B. R. Howard, F. F. Vajdos, S. Li, W. I. Sundquist, C. P. Hill, Structural insights into the catalytic mechanism of cyclophilin A. *Nat Struct Biol* **10**, 475–81 (2003).
62. C. A. Virgen, Z. Kratovac, P. D. Bieniasz, T. Hatzioannou, Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. *Proc Natl Acad Sci U S A* **105**, 3563–8 (2008).
63. D. Sauter, *et al.*, Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. *Cell Host Microbe* **6**, 409–21 (2009).
64. D. Sauter, F. Kirchhoff, Key Viral Adaptations Preceding the AIDS Pandemic. *Cell Host Microbe* **25**, 27–38 (2019).
65. L. Zuliani-Alvarez, *et al.*, Evasion of cGAS and TRIM5 defines pandemic HIV. *Nat Microbiol* **7**, 1762–1776 (2022).
66. A. Yu, *et al.*, TRIM5 α self-assembly and compartmentalization of the HIV-1 viral capsid. *Nat Commun* **11**, 1307 (2020).
67. A. T. Gres, *et al.*, X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. *Science* (1979) **349**, 99–103 (2015).
68. C. Tang, Y. Ndassa, M. F. Summers, Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. *Nat Struct Biol* **9**, 537–43 (2002).

Figure legends

Fig. 1. TRIM5 α depletion in human U-87 MG cells increases non-M HIVs infection in a capsid CYPA binding loop dependent way. (A) Immunoblot of WT and TRIM5 α KO U-87 MG cells. Anti-TRIM5 antibody was used to detect TRIM5 α ; anti-GAPH antibody was used to ensure equal protein loading. (B) WT or TRIM5 α KO U-87 MG cells were infected with equal amounts of luciferase reporter viruses for HIV-1 M, HIV-1 N, HIV-1 O, HIV-1 P, SIVcpzPtt, SIVcpzPts and EIAV. Two to three days later, luciferase activity was measured, infection of KO cells was normalized to infection of WT cells. (C) HIV-1 N, HIV-1 O or HIV-1 P capsids were cloned in HIV-1 M *gag-pol* as replacements for its WT capsid. (D) HIV-1 M *gag-pol* with capsid of either HIV-1 N, O or P were tested in WT and TRIM5 α KO U-87 MG cells. Two to three days after infection, luciferase activity was measured; infection of KO cells was normalized to infection of WT cells. (E) Protein sequence alignment of CYPA binding loop (box) regions of capsids of HIV-1 M, N, O and P and HIV-2. (F) Using their respective *gag-pol* constructs, CYPA binding loop from HIV-1 N or HIV-1 O were introduced in HIV-1 M *gag-pol* and HIV-1 M CYPA binding loop was transferred to HIV-1 N and HIV-1 O *gag-pol*. These CYPA loop mutants were then used to infect WT or TRIM5 α KO U-87 MG cells for two to three days, Luciferase activity was measured, infection of KO

cells was normalized to infection of WT cells. All experiments were repeated for a minimum of three times.

Fig. 2. Capsid residues 88 and 89 mediates susceptibility to huTRIM5 α . (A, B) A88V and G89V capsid mutations for HIV-1 M, (C, D) V88A for HIV-1 N, M88A for HIV-1 O and V88A mutation for HIV-1 P were introduced in their respective *gag-pol* constructs. WT and capsid mutants were tested in infections of WT or TRIM5 α KO U-87 MG cells. Infection of mutant viruses was normalized to infection of corresponding WT virus. (E) GST-pulldown of CYPA (CYPA-GST) with capsid proteins of HIV-1 M, N, O or P. GST: GST not fused to CYPA. Viral lysates and GST-tagged CYPA protein lysates were specifically incubated together with GST Sepharose beads. The eluate was subjected to immunoblotting to detect viral p24 (capsid) and GST-tagged CYPA (pulldown). Cell and viral lysates were also loaded as inputs for GST-tagged CYPA and p24, respectively. (F) Immunoblot of viral particles and corresponding virus producer cells. The level of CYPA packaged by virions was analyzed by anti-HA staining (for CYPA-HA), virus was confirmed by anti-p24 (capsid) antibody staining, anti-tubulin was used to confirm equal amounts of cell lysates loaded. Cells were treated with cyclosporine A (CsA) from 0 to 2.5 μ M. (G) The amount of packaged CYPA in relation to the used CsA dose was quantified using ImageJ.

Fig. 3. Cyclophilin A binds to the CYPA binding loop of HIV-1 M capsid, where it can exert cis/trans isomerase activity at the G89-P90 ω dihedral (36) (A) Overview of the simulated complex. CYPA (shown in gray) binds to the CYPA binding loop (orange) on the surface of the HIV-1 capsid. Monomers are colored differently; the region in the black box is shown as a blowup in panel (B). (B) Close-up view of the CYPA binding loop. The ω dihedral between residues G89 and P90 (shown as sticks) is marked, evaluated as the angle between the normals on the planes formed by the atoms (C_{α} (G89), C(G89), N(P90)) and (C(G89), N(P90), C_{α} (P90)). (C) Potential of mean force (free energy profile) along the ω dihedral of G89-P90 in HIV-1 M wild type with or without CYPA. The height of the energy barrier for the transition from the *trans* (180 $^{\circ}$) to the *cis* (0 $^{\circ}$) conformation is marked with a black line. HIV-1 M capsid without CYPA (red triangle) has a higher isomerization barrier than HIV-1 M bound to CYPA (orange triangle). The height of the free energy difference between *trans* (180 $^{\circ}$) and *cis* (0 $^{\circ}$) conformation is marked with a grey line. HIV-1 M capsid without CYPA (red circle) has a lower free energy difference than HIV-1 M bound to CYPA (orange circle). (D) Barrier heights ($\Delta G^{\#}_{t \rightarrow c}$, triangles) and free energy differences ($\Delta G_{t,c}$, circles) from the potential of mean force computations for the *cis/trans* isomerization of the ω angle between G89 and P90 (Fig. S4). The HIV-1 types and variants are sorted from top to bottom according to the decrease in $\Delta G^{\#}_{t \rightarrow c}$ in the presence of CYPA.

Fig. 4. Wildtype, N66D, H69R or N66D-H69R mutations in CYPA domain of rhTRIMCyp or capsid mutations at position 88 affect rhTRIMCyp antiviral activity in a virus-dependent way. (A) Immunoblot of CrFK cells expressing rhTRIMCyp or its mutants with N66D (rhTRIMCyp.N66D) or H69R (rhTRIMCyp.H69R) or N66D-H69R (rhTRIMCyp.N66D.H69R). (B, C) CrFK cells expressing WT or mutated rhTRIMCyps were infection by luciferase reporter viruses from HIV-1 M, N, O or P or their capsid mutants at position 88. Two to three days after infection, cells were lysed, and luciferase activity was measured. Infectivity of each virus on control cells expressing the empty vector (vector) were used as reference. NH: rhTRIMCyp with N66 and H69 in CYPA domain, DH: rhTRIMCyp with N66D mutation in CYPA, NR: rhTRIMCyp with H69R mutation in CYPA, DR:

rhTRIMCyp with N66D and H69R mutations in CYPA. All experiments were done at least three times in triplicates.

Fig. 5. CYPA knockdown (KD) and CYPA, TRIM5 α double depletion differentially affect infection by HIV-1 M, N, O and P. (A) Immunoblot of CYPA KD in WT and in TRIM5 α knockout (KO) U-87 MG cells. CYPA expression was detected by anti-CYPA antibodies and GAPDH detection served as control for equal protein loading. (B-E) WT and TRIM5 α , CYPA, and double KO U-87 MG cells were infected by HIV luciferase reporter viruses from different groups M, N, O or P for 48 to 72 hrs and luciferase activity was measured. Infection of mutated cells were normalized to infection of WT (vector) cells. (F-I) HIV luciferase reporter viruses from groups M, N, O or P infection, in the presence of increasing amounts of cyclosporine A (CsA), of (F) WT U-87 MG cells, (G) CYPA KD U-87 MG cells, (H) TRIM5 α KO U-87 MG cells, and (I) CYPA KD - TRIM5 α KO U-87 MG cells. Two to three days later, luciferase activity was assessed, and data analysis was done in comparison to control infection. All experiments were repeated at least three times independently with similar findings.

Fig. 1





Fig. 2

Fig. 3




Fig. 4




Fig. 5

